Cordyceps in beverages: NuLiv changes the particle size

An ingredient suitable for a capsule does not automatically work in a beverage. For functional mushroom powders, one difficulty is physical: particles can settle and leave an unwelcome texture. The new Beverage grade of CordycepsPrime, announced by NuLiv Science on 20 October, addresses that obstacle through particle size.

The company declares a mean particle size of 20 micrometres and standardisation to 8% cordycepic acid. It describes the material as liquid-fermented Cordyceps sinensis mycelium without residual substrate; particle size is the difference from the standard grade. The two figures answer different questions: one describes a physical property, the other a compositional marker. Neither measures a health benefit.

Dispersed does not mean dissolved

For formulators, the useful distinction is between dispersion and solubility. In the announcement, the powder remains a dispersion: it is said to settle more slowly and redisperse with gentle agitation. No conversion into a solution is demonstrated. The claim that particles are less perceptible in a beverage is also a company statement, without an independent sensory protocol presented here.

Suggested applications include ready-to-drink beverages, shots, mushroom coffees and shakes. Each matrix nevertheless needs its own assessment of particle distribution, settling over time, redispersibility, taste and the uniformity of the amount actually consumed. A mean particle size does not describe the complete size distribution or, by itself, establish behaviour during storage.

The process also shapes the dose

This is where handling becomes a dose question. If some material remains in the container, the amount added during manufacturing and the amount consumed may differ. That needs measuring in the finished product; the announcement supplies no data to quantify it or calculate a percentage improvement over the earlier grade. The graphic therefore keeps the available specifications separate rather than constructing an assumed sedimentation curve.

The announcement documents a formulation option, rather than a new clinical dossier. Its value for a brand will depend on verifying dispersion in its own recipe and maintaining the connection between material identity, dose and evidence relevant to the intended benefit. Easier handling, if confirmed under those conditions, solves a specific production problem. It does not replace the remaining work.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.